Impact of microdosing clinical study - Why necessary and how useful?

Advanced Drug Delivery Reviews

Volumn 63, Issue 7, 2011, Pages 494-502

  Sugiyama, Yuichi ^a   Yamashita, Shinji ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b SETSUNAN UNIVERSITY   (Japan)

Author keywords

Drug development; Exploratory ind study; Microdose clinical study; Model and simulation; Molecular imaging

Indexed keywords

CLINICAL STUDY; DRUG DEVELOPMENT; EXPLORATORY IND STUDY; MODEL AND SIMULATION; MOLECULAR IMAGING;

DRUG DOSAGE;

ANTINEOPLASTIC AGENT; DIPHENHYDRAMINE; ETHENZAMIDE; VALSPODAR; VERAPAMIL;

ACCURACY; BIOTECHNOLOGY; CHEMICAL COMPOSITION; CLINICAL STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG MICRODOSE; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; DRUG TISSUE LEVEL; DRUG TRANSPORT; EXPLORATORY RESEARCH; HUMAN; IN VITRO STUDY; MOLECULAR IMAGING; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PHYSICAL CHEMISTRY; PREDICTION; PRIORITY JOURNAL; PROBABILITY; REVIEW; STATISTICAL MODEL;

ANIMALS; CLINICAL TRIALS, PHASE I AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUGS, INVESTIGATIONAL; HUMANS; MODELS, BIOLOGICAL; POSITRON-EMISSION TOMOGRAPHY;

EID: 79957782000     PISSN: 0169409X     EISSN: 0169409X     Source Type: Journal    
DOI: 10.1016/j.addr.2010.09.010     Document Type: Review

References (30)

1. Committee for Medical Products for Human Use, Position Paper on non-clinical safety studies to support clinical trials with a single microdose. EMEA, CPMP/SWP/2599/02/Rev 1 (2004).
2. FDA Guidance for Industry. Exploratory IND Studies. Guidance. US Department of Health and Human Services, Food and Drug Administration 2006, Center for Drug Evaluation and Research, Washington DC, USA.
3. Ministry of Health, Labor and Welfare. Guidance. Microdose clinical studies. Ministry of Health, Labor and Welfare 2008, Pharmaceutical and Medical Safety Bureau, Tokyo, Japan.
4. Food and Drug Administration US Department of Health and Human Services, http://www.fda.gov/cder/(2004).
5. Kola I., Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat. Rev. Drug Discov. 2004, 3:711-715.
6. Frank R., Hargreaves R. Clinical biomarkers in drug discovery and development. Nat. Rev. Drug Discov. 2003, 2:566-580.
7. Tashiro M., Duan X., Kato M., Miyake M., Watanuki S., Ishikawa Y., Funaki Y., Iwata R., Itoh M., Yanai K. Brain histamine H1 receptor occupancy of orally administered antihistamines, bepotastine and diphenhydramine, measured by PET with 11C-doxepin. Br. J. Clin. Pharmacol. 2008, 65:811-821.
8. Zhao R., Kalvass J.C., Yanni S.B., Bridges A.S., Pollack G.M. Fexofenadine brain exposure and the influence of blood-brain barrier P-glycoprotein after fexofenadine and terfenadine administration. Drug Metab. Dispos. 2009, 37:29-35.
9. Roberts S.A. Drug metabolism and pharmacokinetics in drug discovery. Curr. Opin. Drug Discov Devel. 2003, 6:66-80.
10. Tang H., Mayersohn M. A novel model for prediction of human drug clearance by allometric scaling. Drug Metab. Dispos. 2005, 33:1297-1303.
11. Mahmood I., Martinez M., Hunter R.P. Interspecies allometric scaling. Part I: prediction of clearance in large animals. J. Vet. Pharmacol. Ther. 2006, 29:415-423.
12. Sharer J.E., Shipley L.A., Vandenbranden M.R., Binkley S.N., Wrighton S.A. Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey. Drug Metab. Dispos. 1995, 23:1231-1241.
13. Takahashi M., Washio T., Suzuki N., Igeta K., Yamashita S. The species differences of intestinal drug absorption and first-pass metabolism between cynomolgus monkeys and humans. J. Pharm. Sci. 2009, 98:4343-4353.
14. Toutain P.L., Ferran A., Bousquet-Mélou A. Species differences in pharmacokinetics and pharmacodynamics. Handb. Exp. Pharmacol. 2010, 199:19-48.
15. Sietsema W.K. The absolute oral bioavailability of selected drugs. Int J Clin Pharmacol Ther Toxcol. 1989, 27:179-211.
16. Komura H., Iwaki M. Species differences in in vitro and in vivo small intestinal metabolism of CYP3A substrates. J. Pharm. Sci. 2008, 97:1775-1800.
17. Akabane T., Tabata K., Kadono K., Sakuda S., Terashita S., Teramura T. A comparison of pharmacokinetics between humans and monkeys. Drug Metab. Dispos. 2010, 38:308-316.
18. Takahashi M., Washio T., Suzuki N., Igeta K., Yamashita S. Investigation of the intestinal permeability and first-pass metabolism of drugs in cynomolgus monkeys using single-pass intestinal perfusion. Biol. Pharm. Bull. 2010, 33:111-116.
19. Lappin G., Kuhnz W., Jochemsen R., Kneer J., Chaudhary A., Oosterhuis B., Drijfhout W.J., Rowland M., Garner R.C. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. Clin. Pharmacol. Ther. 2006, 80:203-215.
20. European Microdosing AMS Partnership Programme (EUMAPP), Outcomes from EUMAPP - A Study comparing in vitro, in silico, microdose and pharmacological dose pharmacokinetics, http://www.eumapp.com/(2008).
21. Igari Y., Sugiyama Y., Awazu S., Hanano M. Comparative physiologically based pharmacokinetics of hexobarbital, phenobarbital and thiopental in the rat. J. Pharmacokinet. Biopharm. 1982, 10:53-75.
22. Iwatsubo T., Hirota N., Ooie T., Suzuki H., Sugiyama Y. Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics. Biopharm. Drug Dispos. 1996, 17:273-310.
23. Kanamitsu S., Ito K., Sugiyama Y. Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver. Pharm. Res. 2000, 17:336-343.
24. Kato M., Shitara Y., Sato H., Yoshisue K., Hirano M., Ikeda T., Sugiyama.Y. The quantitative prediction of CYP-mediated drug interaction by physiologically based pharmacokinetic modeling. Pharm. Res. 2008, 25:1891-1901.
25. Watanabe T., Kusuhara H., Maeda K., Shitara Y., Sugiyama Y. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J. Pharmacol. Exp. Ther. 2009, 328:652-662.
26. Lin J.H., Sugiyama Y., Awazu S., Hanano M. Physiological pharmacokinetics of ethoxybenzamide based on biochemical data obtained in vitro as well as on physiological data. J. Pharmacokinet. Biopharm. 1982, 10:649-661.
27. Iwatsubo T., Hirota N., Ooie T., Suzuki H., Shimada N., Chiba K., Ishizaki T., Green C.E., Tyson C.A., Sugiyama Y. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol. Ther. 1997, 73:147-171.
28. Naritomi Y., Terashita S., Kimura S., Suzuki A., Kagayama A., Sugiyama Y. Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab. Dispos. 2001, 29:1316-1324.
29. Lee Y.J., Maeda J., Kusuhara H., Okauchi T., Inaji M., Nagai Y., Obayashi S., Nakao R., Suzuki K., Sugiyama Y., Suhara T. In vivo evaluation of P-glycoprotein function at the blood-brain barrier in nonhuman primates using [11C]verapamil. J. Pharmacol. Exp. Ther. 2006, 316:647-653.
30. Takano A., Kusuhara H., Suhara T., Ieiri I., Morimoto T., Lee Y.J., Maeda J., Ikoma Y., Ito H., Suzuki K., Sugiyama Y. Evaluation of in vivo P-glycoprotein function at the blood-brain barrier among MDR1 gene polymorphisms by using 11C-verapamil. J. Nucl. Med. 2006, 47:1427-1433.